Scientific Advisory Board

Darron R. Brown, M.D. – Dr. Brown is a world renowned immunologist and expert in the field of infectious diseases. Dr. Brown is currently a Professor of Medicine at the Indiana University School of Medicine, Indianapolis, IN. Dr. Brown is also a Professor of Microbiology and Immunology at the Indiana University School of Medicine. In addition to these duties, Dr. Brown is an attending physician at the Veterans Administration Medical Center and Infectious Diseases Outpatient Clinic, Indianapolis, IN, and also at the Indiana University Medical Center. Dr. Brown is widely regarded as an expert in the field of Human Papillomavirus (HPV) infection and has received several awards and fellowships from the National Institutes of Health, American Cancer Society and the pharmaceutical industry to study various aspects of HPV infection and disease. Dr. Brown has several leading publications in the field of HPV disease and is leading researcher in the field.

Gregory L. Conn, Ph.D., Chief Scientific Officer. - Dr. Conn has over 35 years of drug development expertise, including the development of antiviral and anticancer drugs. Dr. Conn has experience taking drugs through complete development and commercialization. He is a graduate of the Albert Einstein College of Medicine, where he obtained both his M.S. and Ph.D. in biochemistry. Dr. Conn started his professional career at Merck, Sharpe and Dohme. He was a leading scientist at Regeneron Pharmaceuticals, where he established and headed various groups in the Cell and Molecular Biology and Drug Discovery departments. He was a Director in the Process Development department at Covance Biotechnology Services Inc., a contract research and development and drug manufacturing organization. He supervised both the Analytical Development teams which were responsible for all drug characterization, method development and drug stability studies and program teams developing drug manufacturing processes. He has expertise across all phases of the drug development process including commercialization of drugs, FDA and regulatory requirements. He is also the co-inventor of 8 drug patents.

Mark Einstein, M.D. - Dr. Einstein is one of the world’s leading experts in HPV disease including cervical cancer. He is currently an attending physician in the department of Obstetrics and Gynecology at the Jacobi Medical center in NY. He is also the Director of Clinical Research, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Women’s Health at the Albert Einstein Cancer Center and the Montefiore Medical Center in NY. He is a tenure track professor of Gynecologic Oncology at the Albert Einstein College of Medicine. Dr. Einstein has published widely in the field of HPV-related cancer and oncology. He has worked with the FDA in designing clinical trials for cervical cancer and has been a clinical consultant to several companies including Merck during the development of Gardasil®. Dr. Einstien is a peer reviewer for leading cancer and infectious disease journals. He has received several NIH, WHO and NCI awards to study HPV infections and cancers.

Leaf Huang, Ph.D. – Dr. Huang is the Fred N. Eshelman Distinguished Professor and Chair, Division of Molecular Pharmaceutics, University of North Carolina, Chapel Hill. He is a renowned expert in the field of drug delivery and is the inventor of PDS Biotechnology Corporation’s Versamune™ technology and a cofounder of the company. Dr. Huang’s research has been in the areas of gene therapy and drug delivery. He produced the first ever liposome gene-delivery clinical trial in 1992. In 2004, he received the Alec D. Bangham Achievement Award, the highest honor in liposome drug delivery. He co-founded LipoGen and Rgene. Both companies were sold successfully. Dr. Huang holds a B.S. in physics and a Ph.D. in biophysics from Michigan State University.

Lisa Rohan, Ph.D. - Dr. Rohan currently holds appointments as Associate Professor in the Department of Pharmaceutical Sciences in the School of Pharmacy and the Department of Obstetrics, Gynecology, and Reproductive Sciences in the School of Medicine at the University of Pittsburgh. Additionally, she is an Assistant Investigator at the Magee Women’s Research Institute where among her other duties she holds a position on the Biotechnology Advisory Board for the Institute. She was formerly Director of Clinical Studies at Biodecision Laboratories and very frequently dealt with the FDA in designing and implementing clinical studies. She is an expert in drug delivery and the development of drugs for infectious disease. Dr. Rohan obtained a B.S. in chemical engineering from West Virginia University and a Ph.D. in pharmaceutics from the University of Pittsburgh.

Jerold G. Woodward, Ph.D. - Prof. Woodward is currently Professor, Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky College of Medicine. Prof. Woodward is an expert immunologist and has a wealth of experience working with nanoparticles and humanized transgenic mouse models. Ongoing projects in Prof. Woodward’s lab involve the role of different tissues in peripheral tolerance induction using the eye as a model system, the role of the antigen presenting cell in tolerance induction, the ability of tumor cells to escape immune recognition by inducing a state of tolerance and, the production of transgenic mice as models of autoimmune disease to study the role of tolerance in regulating autoimmunity. Prof. Woodward obtained his Ph.D. at the University of Utah and did postdoctoral studies at the University of Southern California.